Literature DB >> 7504958

Tenascin and other adhesion-modulating proteins in cancer.

R Chiquet-Ehrismann1.   

Abstract

A loss in cell-cell adhesion and an increase in cell motility are clearly prerequisites for the development of invasive tumors and metastasis. Since disseminating tumor cells have to interact with and migrate through extracellular matrices it is of interest to compare the composition of extracellular matrix proteins in normal and tumor tissues, in order to determine whether the extracellular matrix could be critically involved in affecting tumor cell adhesion and migration. The question will be addressed whether tumor extracellular matrix contains increased amounts of potentially antiadhesive extracellular matrix components and whether cells behave differently depending on the extracellular matrix they encounter. The results reviewed support the hypothesis that changes in the extracellular matrix and the cellular receptors are indeed important in the process of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504958

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  20 in total

1.  The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones.

Authors:  Seiichi Munesue; Yuri Kusano; Kayoko Oguri; Naoki Itano; Yasuo Yoshitomi; Hayao Nakanishi; Ikuo Yamashina; Minoru Okayama
Journal:  Biochem J       Date:  2002-04-15       Impact factor: 3.857

2.  Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes.

Authors:  D Fischer; R P Tucker; R Chiquet-Ehrismann; J C Adams
Journal:  Mol Biol Cell       Date:  1997-10       Impact factor: 4.138

3.  Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin alpha 8 beta 1 receptor interactions with tenascin: murine alpha 8 beta 1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C.

Authors:  S Denda; U Müller; K L Crossin; H P Erickson; L F Reichardt
Journal:  Biochemistry       Date:  1998-04-21       Impact factor: 3.162

Review 4.  The extracellular matrix of the hematopoietic microenvironment.

Authors:  G Klein
Journal:  Experientia       Date:  1995-09-29

5.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

6.  Accessing key steps of human tumor progression in vivo by using an avian embryo model.

Authors:  Martin Hagedorn; Sophie Javerzat; Delphine Gilges; Aurélie Meyre; Benjamin de Lafarge; Anne Eichmann; Andreas Bikfalvi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

7.  SPARC gene expression is repressed in human urothelial cells (UROtsa) exposed to or malignantly transformed by cadmium or arsenite.

Authors:  Jennifer Larson; Tahmina Yasmin; Donald A Sens; Xu Dong Zhou; Mary Ann Sens; Scott H Garrett; Jane R Dunlevy; Ling Cao; Seema Somji
Journal:  Toxicol Lett       Date:  2010-09-16       Impact factor: 4.372

8.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

Authors:  B Carnemolla; P Castellani; M Ponassi; L Borsi; S Urbini; G Nicolo; A Dorcaratto; G Viale; G Winter; D Neri; L Zardi
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

9.  Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.

Authors:  U Gabler; A Berndt; H Kosmehl; U Mandel; L Zardi; S Müller; A Stelzner; D Katenkamp
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

Review 10.  Tenascins, a growing family of extracellular matrix proteins.

Authors:  R Chiquet-Ehrismann
Journal:  Experientia       Date:  1995-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.